MindBio Completes 6-Month Post Treatment Milestone in Microdosing Depression Trial
Exciting data release to follow.
Read issue →MindBio Develops Long Term Shelf-Stable Microdosing Formulation
Stability of microdosing formulation at room temperature, assessed at 12 months
Read issue →MindBio enters 25th participant into triple blind, double dummy, active placebo controlled microdosing trial in depressed patients
Phase 2B Microdosing Depression Trial Update
Read issue →MindBio provides update on government approved take-home microdosing clinical trials
Clinical trials update, PMS, PMDD, Depression and More!
Read issue →MindBio Appoints Haywood Securities to Conduct Strategic Investment Advisory
Haywood to conduct strategic investment advisory for MindBio
Read issue →MindBio Therapeutics CEO issues letter to Shareholders
CEO Update
Read issue →Microdosing Improves Psychological Outcomes in World First Gov Approved Take-Home Trials
Secondary Data and Safety Results in Depressed Patients from Phase 2A Depression Trial
Read issue →Microdosing for Depression: Biotechs Sign $66.5M Deal to Out License Novel Psilocin Prodrug Candidate
Latest News From MindBio
Read issue →